Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)

Ítems similars

• Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria
  per: Iking-Konert, Christof, et al.
  Publicat: (2011)
• Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
  per: Burmester, Gerd R, et al.
  Publicat: (2016)
• Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)
  per: Burmester, Gerd R, et al.
  Publicat: (2016)
• Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study
  per: Strand, Vibeke, et al.
  Publicat: (2012)
• Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab
  per: Rubbert-Roth, Andrea, et al.
  Publicat: (2016)